Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial

AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains. Icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, added to a statin was shown to reduce initial CV event...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Heart J
Autori principali: Budoff, Matthew J, Bhatt, Deepak L, Kinninger, April, Lakshmanan, Suvasini, Muhlestein, Joseph B, Le, Viet T, May, Heidi T, Shaikh, Kashif, Shekar, Chandana, Roy, Sion K, Tayek, John, Nelson, John R
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Fast Track Congress
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7654934/
https://ncbi.nlm.nih.gov/pubmed/32860032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa652
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi